GHRS Stock Analysis: Buy, Sell, or Hold?
GHRS - GH Research PLC Ordinary Shares
$26.77
1.42 (5.60%)
▲
5d:
-0.45%
30d:
+29.57%
90d:
+63.83%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 06, 2026
21d
Get Alerted When GHRS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GHRS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: GHRS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GHRS is currently trading at $26.77, which is considered slightly high relative to its 30-day fair value range of $21.20 to $27.01.
Technical Outlook: Technically, GHRS is in a strong uptrend. Immediate support is located at $25.00, while resistance sits at $28.59. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.50 (+47.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GHRS is in a strong uptrend. Immediate support is located at $25.00, while resistance sits at $28.59. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.50 (+47.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$21.20 -
$27.01
Company Quality Score
56/100
(HOLD)
Options IV Signal
33th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
71.7%
All Signals
- NEUTRAL: Options fairly priced (IV 33th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.6%)
- BULLISH: Trading 47.6% below Wall St target ($39.50)
Trading Range Analysis
30-Day Trading Range
$21.20 -
$27.01
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$3.14
(11.7%)
Support & Resistance Levels
Support Level
$25.00
Resistance Level
$28.59
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-13.39
Wall Street Target
$39.50
(+47.6%)
Share & Embed Analysis
Last updated: July 14, 2026 9:25 PM ET
Data refreshes hourly during market hours. Next update: 10:25 PM
Data refreshes hourly during market hours. Next update: 10:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GHRS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 51 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 60 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
